Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine

PHASE3CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

May 8, 2024

Primary Completion Date

February 12, 2025

Study Completion Date

May 8, 2025

Conditions
Acute Pain
Interventions
DRUG

Bupivacaine Liposome 13.3 Milligrams/Milliliter [Exparel]

Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.

DRUG

Dexmedetomidine 0.5milligram (50micrograms)

Dexmedetomidine is a full α₂ adrenergic receptor agonist roughly eight times more selective for the α₂ receptor than clonidine.

Trial Locations (1)

Unknown

The University of Hong Kong, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT06235606 - Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine | Biotech Hunter | Biotech Hunter